J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

AnaptysBio holds the No. 137 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG Therapeutics TGTX and Harmony Biosciences HRMY are among the top 5 highly rated stocks ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stagebiotechnology company, announced positive results from its GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab, a treatment for ...